Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats

Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats

Background and Aim. The impact of Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition on glycemic indices in diabetes mellitus remains far from clear. We explored the effects of PCSK9 inhibition on glycemic indices in the diabetes rat model. Methods. To prepare the anti-PCSK9 vaccine, a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Elham Abdollahi, Maciej Banach, Amirhossein Sahebkar
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Journal of Diabetes Research
Online Access:	http://dx.doi.org/10.1155/2021/4757170
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

PCSK7 levels in women with and without PCOS
by: Stephen L. Atkin, et al.
Published: (2024-12-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

PCSK9 Inhibitors: The Evolving Future
by: Bijay Mukesh Jeswani, et al.
Published: (2024-11-01)

PCSK9: A Potential Therapeutic Target for Sepsis
by: Yuan Yuan, et al.
Published: (2020-01-01)

Protective effect of alirocumab, a PCSK9 inhibitor, on the sciatic nerve of rats with diabetic peripheral neuropathy
by: Na Cui, et al.
Published: (2024-03-01)

Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
by: Zhenzhen Li, et al.
Published: (2024-11-01)

Carotenoid Interactions with PCSK9: Exploring Novel Cholesterol-Lowering Strategies
by: Alessandro Medoro, et al.
Published: (2024-11-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

PCSK9 affects vascular senescence through the SIRT1 pathway
by: Yuqin Wang, et al.
Published: (2025-03-01)

PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation
by: Elena Dozio, et al.
Published: (2020-01-01)

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
by: Ewelina Jakielska, et al.
Published: (2023-03-01)

Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
by: Emilie Wong Chong, et al.
Published: (2022-10-01)

The Effects of Raspberry Consumption on Glycemic Control and Inflammation Markers in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Mostafa Shahraki Jazinaki, et al.
Published: (2024-06-01)

Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies
by: Chen Gurevitz, et al.
Published: (2024-12-01)

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
by: Xue-Ying Zhang, et al.
Published: (2025-02-01)

Idiosyncratic Drug-Induced Liver Injury in a Healthy Patient following PCSK9-Inhibitor Injection
by: B.-O. Stüben, et al.
Published: (2024-01-01)

Correction: Circulating levels of PCSK9, ANGPTL3 and lp(a) in stage III breast cancers
by: Emilie Wong Chong, et al.
Published: (2024-11-01)

Retraction Note: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
by: Khursheed Muzammil, et al.
Published: (2024-11-01)

RETRACTED ARTICLE: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
by: Khursheed Muzammil, et al.
Published: (2024-03-01)

Dietary glycemic and insulin indices with the risk of osteoporosis: results from the Iranian teachers cohort study
by: Anahita HoushiarRad, et al.
Published: (2025-01-01)

Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children
by: Olesya Fedoryak, et al.
Published: (2020-01-01)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022-01-01)

Isolation of PCSK9-specific nanobodies from synthetic libraries using a combined protein selection strategy
by: Apisitt Thaiprayoon, et al.
Published: (2025-01-01)

Evaluation of serum and salivary PCSK9 and IL6 and its association with periodontal inflammation and atherosclerotic cardiovascular diseases
by: Roshan R. Rughwani, et al.
Published: (2022-09-01)

Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records.
by: Giulia Barbati, et al.
Published: (2024-01-01)

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
by: José Seijas-Amigo, et al.
Published: (2021-05-01)

Exploring research trends and hotspots on PCSK9 inhibitor studies: a bibliometric and visual analysis spanning 2007 to 2023
by: Ping Lai, et al.
Published: (2024-11-01)

Analysis of changes in PCSK9 and TNF-α concentrations in response to physical exercises using virtual reality in patients in the fifth stage of chronic kidney disease undergoing hemodialysis
by: Agnieszka Turoń-Skrzypińska, et al.
Published: (2025-01-01)

New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia
by: Sushmitha Duddu, et al.
Published: (2025-01-01)

The protective effects of sesamin against metabolic syndrome: A mechanistic review
by: Elham Parsa, et al.
Published: (2024-11-01)

Comprehensive Assessment of PCSK9 Inhibitors for Lipid Management: Scientific Guidance Based on Drug Selection Recommendations for Chinese Medical Institutions
by: Li J, et al.
Published: (2024-12-01)

PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk
by: Radosław Szydłowski, et al.
Published: (2024-12-01)

Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease
by: Cristiana-Elena Vlad, et al.
Published: (2019-01-01)

Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
by: Xiaocui Chen, et al.
Published: (2025-03-01)

Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes
by: Małgorzata Waluś-Miarka, et al.
Published: (2021-01-01)

Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers
by: Ping Jin, et al.
Published: (2025-01-01)

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis
by: Yue Zhang, et al.
Published: (2022-01-01)

The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes
by: Zeki Dogan, et al.
Published: (2025-02-01)

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
by: Shengxuan Zhang, et al.
Published: (2024-11-01)